Lilly's Taltz wins third approval, this time in patients with active ankylosing spondylitis
Lilly’s monoclonal antibody, Taltz, which is already approved for psoriatic arthritis and plaque psoriasis has won its third approval. The FDA has cleared its use in active ankylosing spondylitis (AS), a chronic inflammatory rheumatic disorder that affects the pelvic joints and spine, and can be characterized by inflammatory back pain, stiffness and impaired function and mobility.
Taltz — akin to Novartis’ $NVS blockbuster Cosentyx — inhibits IL-17A, a cytokine involved in inflammatory and immune responses. The drug, which will now also address the roughly 1.6 million Americans with AS, generated about $354 million in the second quarter.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.